My SciELO
Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Archivos de la Sociedad Española de Oftalmología
Print version ISSN 0365-6691
Abstract
ALVAREZ-RIVERA, L.G. et al. Coat's disease treated with bevacizumab (Avastin®). Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.5, pp.329-331. ISSN 0365-6691.
Case Report: We report a case of Coats disease in a 10-year-old-girl who presented with a profound visual deficit, exudative retinal detachment, vascular telangiectasias and subretinal lipid, who underwent treatment with an intravitreal injection of bevacizumab (AVASTIN™). Serial examinations documented an involutional response with a reduction of the subretinal fluid, exudates and macular thickness. Discussion: The aetiology of Coats disease remains uncertain, as does its optimal management. Although resolution of a case depends partially on age, and can even occur spontaneously on rare occasions, intravitreal injections of bevacizumab should be considered when planning treatment.
Keywords : Vascular endothelial growth factor; Coats disease; monoclonal antibodies; angiogenesis inhibitors; telangiectatic retinal vessels.